|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
GB8620926D0
(en)
|
1986-08-29 |
1986-10-08 |
Delta Biotechnology Ltd |
Yeast promoter
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
CA2441903C
(en)
*
|
2000-05-26 |
2012-07-31 |
National Research Council Of Canada |
Single-domain brain-targeting antibody fragments derived from llama antibodies
|
|
EP1673395A1
(en)
|
2003-10-15 |
2006-06-28 |
PDL BioPharma, Inc. |
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
WO2006130374A2
(en)
|
2005-05-27 |
2006-12-07 |
Biogen Idec Ma Inc. |
Tweak binding antibodies
|
|
PT2548560E
(pt)
|
2005-06-23 |
2015-09-22 |
Isis Pharmaceuticals Inc |
Composições e métodos de modulação da excisão-união de smn2
|
|
ATE526345T1
(de)
|
2005-08-31 |
2011-10-15 |
Univ Laval |
Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit
|
|
US7846445B2
(en)
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
HUE033325T2
(en)
|
2007-01-05 |
2017-11-28 |
Univ Zuerich |
Anti-beta-amyloid binder antibodies and their use
|
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
EP2315779A2
(en)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
|
HRP20150831T1
(hr)
|
2008-12-19 |
2015-10-09 |
Biogen International Neuroscience Gmbh |
Humana anti-alfa- sinuklein auto-protutijela
|
|
JP2012515556A
(ja)
|
2009-01-23 |
2012-07-12 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
WO2010144508A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
PE20121539A1
(es)
|
2009-06-08 |
2012-12-06 |
Amunix Operating Inc |
Polipeptidos de la hormona de crecimiento y metodos de preparacion
|
|
KR20220084437A
(ko)
|
2009-06-17 |
2022-06-21 |
바이오젠 엠에이 인코포레이티드 |
대상에게서 smn2 스플라이싱을 조정하기 위한 조성물 및 방법
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
|
AU2010311332B2
(en)
|
2009-10-30 |
2015-04-23 |
Albumedix Ltd. |
Albumin variants
|
|
WO2011103076A1
(en)
|
2010-02-16 |
2011-08-25 |
Medlmmune, Llc |
Hsa-related compositions and methods of use
|
|
PH12012501744A1
(en)
*
|
2010-03-03 |
2021-08-09 |
Boehringer Ingelheim Int |
Biparatopic abeta binding polypeptides
|
|
KR20130070576A
(ko)
|
2010-04-09 |
2013-06-27 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 유도체 및 변이체
|
|
US20130017997A1
(en)
|
2010-08-19 |
2013-01-17 |
Amunix Operating Inc. |
Factor VIII Compositions and Methods of Making and Using Same
|
|
LT2627672T
(lt)
|
2010-10-11 |
2018-12-10 |
Biogen International Neuroscience Gmbh |
Žmogaus antikūnai prieš tau baltymą
|
|
WO2012059486A1
(en)
|
2010-11-01 |
2012-05-10 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
|
CN103380145B
(zh)
|
2010-12-17 |
2016-10-12 |
生物控股有限公司 |
人类抗-sod1抗体
|
|
US9045564B2
(en)
|
2011-02-15 |
2015-06-02 |
Medimmune, Llc |
HSA-related compositions and methods of use
|
|
EP2675471A4
(en)
|
2011-02-15 |
2015-01-28 |
Medimmune Llc |
HSA-RELATED COMPOSITIONS AND USE PROCESSES
|
|
WO2012150319A1
(en)
|
2011-05-05 |
2012-11-08 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
|
PL2723379T3
(pl)
|
2011-06-23 |
2019-05-31 |
Biogen Int Neuroscience Gmbh |
Cząsteczki wiążące przeciwko alfa-synukleinie
|
|
SI2766397T1
(sl)
|
2011-10-11 |
2018-09-28 |
F. Hoffmann-La Roche Ag |
Izboljšano sestavljanje bispecifičnih protiteles
|
|
CA2853412C
(en)
|
2011-10-28 |
2021-05-04 |
University Of Zurich |
Tdp-43 specific binding molecules
|
|
CN104159922B
(zh)
*
|
2012-01-10 |
2018-03-02 |
比奥根Ma公司 |
对转运治疗性分子穿过血脑屏障的增强
|
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
EP2885010B1
(en)
|
2012-08-16 |
2020-01-01 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
|
JP6284548B2
(ja)
|
2012-12-21 |
2018-02-28 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
ヒト抗タウ抗体
|
|
US8980270B2
(en)
|
2013-01-18 |
2015-03-17 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
|
AU2014217831A1
(en)
|
2013-02-16 |
2015-07-16 |
Albumedix Ltd. |
Pharmacokinetic animal model
|
|
KR102042174B1
(ko)
*
|
2013-03-29 |
2019-11-08 |
삼성전자주식회사 |
인간화 및 친화도 성숙된 항 c-Met 항체 및 그의 용도
|
|
WO2014179657A1
(en)
|
2013-05-03 |
2014-11-06 |
Eleven Biotherapeutics, Inc. |
Albumin variants binding to fcrn
|
|
CA2960925A1
(en)
|
2014-09-30 |
2016-04-07 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
|
EP3233922B1
(en)
*
|
2014-12-19 |
2022-05-11 |
MedImmune Limited |
Blood brain barrier transport molecules and uses thereof
|
|
AU2016210835B2
(en)
*
|
2015-01-29 |
2021-01-21 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
|
|
WO2017106462A1
(en)
|
2015-12-18 |
2017-06-22 |
Biogen Ma Inc. |
Bispecific antibody platform
|
|
MX389765B
(es)
*
|
2016-07-06 |
2025-03-20 |
Nat Res Council Canada |
Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
|
|
US10906973B2
(en)
*
|
2016-12-12 |
2021-02-02 |
National Research Council Of Canada |
Antibody variants transmigrating the blood-brain barrier and uses thereof
|
|
JP7449092B2
(ja)
*
|
2017-01-30 |
2024-03-13 |
ナショナル リサーチ カウンシル オブ カナダ |
血液脳関門移動化合物及びその使用
|
|
CA3059938A1
(en)
*
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|